Drug intelligence / Profile preview

LPT-301

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-301 is an investigational ophthalmic solution being developed by LitePharmTech. It is classified as an Incrementally Modified Drug (IMD) or improved medical device/drug, suggesting it is an optimized version of an existing therapeutic or a drug-device combination. As of early 2024, the project is in the preclinical stage of development for ophthalmic indications. Specific details regarding its active ingredient, molecular target, and exact clinical application have not been disclosed.

Beyond the preview

Go deeper on LPT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-301.

Explore the full profile